For the side effect
nobody warns you about
The nausea on a GLP-1 gets discussed endlessly. The other one does not: a flattening of drive, libido, motivation and the ability to enjoy things — and for some people, difficulty finishing. It is the reason a lot of people quit a drug that was otherwise working for them.
This is a daily capsule aimed squarely at that. It carries dopamine precursor substrate at two different points in the pathway, the cofactor both conversions actually need, and a ginger extract for the nausea that makes people stop before anything else has a chance to settle.
It builds over weeks rather than working on the day. If you want something for tonight, this is the wrong product on this page — keep reading and we will point you at the right one.
The mechanism that makes it work is the same one that flattens you.
The appetite suppression on a GLP-1 runs through reward signalling. Research describes GLP-1 receptor activity at the hypothalamus as reducing central dopamine and norepinephrine release — which is exactly how food stops being interesting. The difficulty is that the reward pathway does not only handle food. The first published case report attributing anorgasmia to GLP-1 therapy puts the mechanism there (Visvabharathy, Sexual Medicine, 2025).
You cannot turn that down for food alone. So the question becomes whether the substrate side can be supported while the drug does its work.
Two entry points into the same pathway
Dopamine is built in steps: tyrosine becomes L-DOPA, and L-DOPA becomes dopamine. Under sustained GLP-1 therapy, turnover runs above what the baseline substrate pool comfortably supplies. Published work on GLP-1 anhedonia has converged on tyrosine at 500–1000 mg daily as the first thing to try, which is where the 500 mg dose here comes from.
Mucuna pruriens enters the same pathway one step later. The seed extract naturally contains L-DOPA, so it arrives already past the first conversion. Standardised to 15%, 200 mg carries roughly 30 mg of L-DOPA — far below the doses used in Parkinson's therapy, and intended as substrate rather than replacement. Some published comparisons describe whole Mucuna extract performing better than isolated L-DOPA at matched doses, which is usually attributed to cofactors carried in the plant matrix.
Plain L-tyrosine, not the acetylated one
N-acetyl L-tyrosine sells better because it sounds more advanced. The pharmacokinetic work does not support it for oral use: NALT has been reported to raise plasma tyrosine by roughly 0–25%, against 130–276% for plain L-tyrosine. It was developed for intravenous nutrition, where solubility is the constraint that matters. Taken by mouth, the plain form is the one that shows up in the blood, so that is what is in here.
Why tyrosine "doesn't work" for some people
Both conversions in that pathway need vitamin B6 as a cofactor — directly for the step that makes dopamine from L-DOPA, and indirectly for the step before it. Without enough of it, precursor sits in circulation without converting efficiently. That is the usual explanation offered for the fairly common report that tyrosine did nothing, and subclinical B6 insufficiency is not rare.
The B6 here is pyridoxal-5-phosphate, the form the body uses directly, rather than pyridoxine hydrochloride which has to be converted first. 5 mg per dose sits far below the tolerable upper intake level and is there to keep the cofactor from becoming the limiting step under daily use.
The ginger is not filler
Nausea is the most common reason people abandon a GLP-1 during titration — usually in the first eight weeks, which is exactly the window where this capsule has not finished building yet. Ginger extract standardised to 5% gingerols acts on 5-HT₃ receptors, the same target class as ondansetron, alongside an effect on gastric emptying.
100 mg per dose is at the lower end of the studied range, which runs to 1,000 mg in settings like chemotherapy-induced nausea. It is not sedating, carries no anticholinergic effect, and has no known interaction with GLP-1 medications.
Every ingredient, every milligram
Two capsules is one dose. A 30-day bottle is 60 capsules.
| Ingredient | Per capsule | Per dose | Why it is here |
|---|---|---|---|
| L-Tyrosine | 250 mg | 500 mg | Dopamine synthesis precursor — two enzymatic steps out |
| Mucuna pruriens extract, 15% L-DOPA | 100 mg | 200 mg (= 30 mg L-DOPA) | Direct precursor — one enzymatic step out |
| Ginger extract, 5% gingerols | 50 mg | 100 mg | Nausea — 5-HT₃ antagonism, the ondansetron class |
| Pyridoxal-5-phosphate (active B6) | 2.5 mg | 5 mg | Cofactor both conversions depend on |
| Colloidal silicon dioxide NF | 3 mg | 6 mg | Flow agent — the only inactive ingredient |
| Total fill weight | 405.5 mg | 811 mg | Size 00 HPMC capsule, ~735 mg capacity |
The standardisation is the whole formula
Mucuna pruriens L-DOPA content varies from about 1% to 15% depending on supplier and batch. An unstandardised extract at the same milligram weight can therefore deliver anywhere from a fifteenth of the intended dose to all of it. This formula is built on 15% standardisation confirmed by certificate of analysis, and we assay blend uniformity for L-DOPA content across the batch rather than trusting the paperwork alone. Any product in this category that will not tell you its standardisation is not telling you its dose.
How it runs
Morning dosing lines up with the natural dopamine circadian rhythm, and food smooths the ginger while keeping tyrosine off an empty stomach. This is not a stimulant and not a take-it-when-you-need-it product — if nothing has changed by day three, that is expected, not a failure.
Where it sits next to the other two
Three different problems, three different timescales. They are not alternatives to each other and they can be run together.
| Product | When | Onset | What it addresses |
|---|---|---|---|
| LoveLife | Every morning | 2–4 weeks | Baseline drive and reward tone while GLP-1 therapy continues |
| SexyTime | As needed | 15–30 min | Acute libido, nasal spray |
| SuperCLIMAX | As needed | ~45 min | Difficulty finishing specifically — injectable |
Who should not take this
Mucuna is pharmacologically active, not a gentle botanical. These are genuine contraindications and we would rather lose the sale than bury them.
- Levodopa or carbidopa (Sinemet, Rytary) — the L-DOPA is additive.
- MAO inhibitors (selegiline, rasagiline, phenelzine, tranylcypromine, moclobemide) — hypertensive crisis risk.
- Antipsychotics, typical or atypical (haloperidol, risperidone, olanzapine and others) — opposing mechanism.
- Dopamine agonists (pramipexole, ropinirole) — additive dopaminergic effect.
- Pregnancy or breastfeeding — no safety data for Mucuna.
Discuss with a prescriber first if any of the following apply:
- Hyperthyroidism — tyrosine is also a thyroid hormone precursor.
- History of melanoma — unresolved theoretical concern with dopamine precursors.
- SSRIs — theoretical interaction, clinically uncommon.
- Bipolar disorder — dopamine substrate warrants prescriber oversight.
What people report in the first week
Mild nausea from the Mucuna, distinct from GLP-1 nausea and usually settling on its own. Vivid dreams or lighter sleep in some people, consistent with a shift in dopamine timing. Occasionally a transient headache. Some people describe an early lift they read as feeling wired — in most reports that settles as things level out, but if it does not, stop and talk to a prescriber.
What this is, formally
A dietary supplement under DSHEA. L-tyrosine, Mucuna pruriens, ginger and pyridoxal-5-phosphate are all established dietary ingredients. Capsule shell is size 00 vegetable HPMC. Statements about these ingredients have not been evaluated by the Food and Drug Administration, and this product is not intended to diagnose, treat, cure or prevent any disease.